ArticleMolecular cancer therapeutics2022

Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.

Pavlina Spiliopoulou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.